Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis

The Pharmacogenomics Journal volume 18, pages 70–75 (2018)Cite this article

Subjects

Abstract

Anti-tumor necrosis factor (anti-TNF) drugs are effective against psoriasis, although 20–30% of patients are nonresponders. Few pharmacogenomic studies have been performed to predict the response to anti-TNF drugs in psoriasis. We studied 173 polymorphisms to establish an association with the response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis (N=144). We evaluated the response using PASI75 at 3, 6 and 12 months. The results of the multivariate analysis showed an association between polymorphisms in PGLYR4, ZNF816A, CTNNA2, IL12B, MAP3K1 and HLA-C genes and the response at 3 months. Besides, the results for polymorphisms in IL12B and MAP3K1 were replicated at 6 months. We also obtained significant results for IL12B polymorphism at 1 year. Moreover, polymorphisms in FCGR2A, HTR2A and CDKAL1 were significant at 6 months. This is the first study to show an association with these polymorphisms. However, these biomarkers should be validated in large-scale studies before implementation in clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Prieto-Pérez R, Cabaleiro T, Dauden E, Ochoa D, Roman M, Abad-Santos F . Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis 2013; 2013: 613086.

    PubMed  PubMed Central  Google Scholar 

  2. Prieto-Pérez R, Cabaleiro T, Dauden E, Abad-Santos F . Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013; 13: 297–305.

    Article  Google Scholar 

  3. Prieto-Pérez R, Cabaleiro T, Dauden E, Ochoa D, Roman M, Abad-Santos F . Pharmacogenetics of topical and systemic treatment of psoriasis. Pharmacogenomics 2013; 14: 1623–1634.

    Article  Google Scholar 

  4. Julià A, Ferrándiz C, Daudén E, Fonseca E, Fernández-López E, Sanchez-Carazo JL et al. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J 2014; 15: 322–325.

    Article  Google Scholar 

  5. Ryan C, Kelleher J, Fagan MF, Rogers S, Collins P, Barker JN et al. Genetic markers of treatment response to tumour necrosis factor-alpha inhibitors in the treatment of psoriasis. Clin Exp Dermatol 2014; 39: 519–524.

    Article  CAS  Google Scholar 

  6. Gallo E, Cabaleiro T, Roman M, Solano-Lopez G, Abad-Santos F, Garcia-Diez A et al. The relationship between TNF-alpha promoter and IL12B/IL23R gene polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case control study. Br J Dermatol 2013; 169: 819–829.

    Article  CAS  Google Scholar 

  7. Batalla A, Coto E, Gonzalez-Fernandez D, Gonzalez-Lara L, Gomez J, Santos-Juanes J et al. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. Pharmacogenet Genomics 2015; 25: 313–316.

    CAS  PubMed  Google Scholar 

  8. Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V . Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 2012; 16: 29–34.

    Article  CAS  Google Scholar 

  9. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P . TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132: 596–600.

    Article  Google Scholar 

  10. Di Renzo L, Bianchi A, Saraceno R, Calabrese V, Cornelius C, Iacopino L et al. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-alpha blockers. Pharmacogenet Genomics 2012; 22: 134–142.

    Article  CAS  Google Scholar 

  11. Gonzalez-Lara L, Batalla A, Coto E, Gomez J, Eiris N, Santos-Juanes J et al. The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. Arch Dermatol Res 2014; 307: 405–412.

    Article  Google Scholar 

  12. Julià M, Guilabert A, Lozano F, Suarez-Casasus B, Moreno N, Carrascosa JM et al. The role of Fcgamma receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis: a pharmacogenetic study. JAMA Dermatol 2013; 149: 1033–1039.

    Article  Google Scholar 

  13. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths C, Nast A et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.

    Article  CAS  Google Scholar 

  14. Prieto-Pérez R, Solano-Lopez G, Cabaleiro T, Roman M, Ochoa D, Talegon M et al. New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study. Br J Dermatol 2015; 172: 1432–1435.

    Article  Google Scholar 

  15. Solé X, Guino E, Valls J, Iniesta R, Moreno V . SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928–1929.

    Article  Google Scholar 

  16. González JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644–645.

    PubMed  Google Scholar 

  17. van Lumig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM . Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013; 68: 57–63.

    Article  Google Scholar 

  18. Sun C, Mathur P, Dupuis J, Tizard R, Ticho B, Crowell T et al. Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21. Hum Genet 2006; 119: 113–125.

    Article  CAS  Google Scholar 

  19. Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010; 42: 1005–1009.

    Article  CAS  Google Scholar 

  20. Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 2014; 46: 45–50.

    Article  CAS  Google Scholar 

  21. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.

    Article  Google Scholar 

  22. Zulfiqar F, Hozo I, Rangarajan S, Mariuzza RA, Dziarski R, Gupta D . Genetic association of peptidoglycan recognition protein variants with inflammatory bowel disease. PLoS One 2013; 8: e67393.

    Article  CAS  Google Scholar 

  23. Kainu K, Kivinen K, Zucchelli M, Suomela S, Kere J, Inerot A et al. Association of psoriasis to PGLYRP and SPRR genes at PSORS4 locus on 1q shows heterogeneity between Finnish, Swedish and Irish families. Exp Dermatol 2009; 18: 109–115.

    Article  CAS  Google Scholar 

  24. El-Wahed Gaber MA, El-Halim Kandil MA, El-Farargy SM, Galbet DA . Beta-catenin expression in psoriasis. Indian Dermatol Online J 2015; 6: 13–16.

    Article  Google Scholar 

  25. Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009; 5: e1000606.

    Article  Google Scholar 

  26. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42: 991–995.

    Article  CAS  Google Scholar 

  27. Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M et al. Pharmacogenetics of psoriasis: HLACw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to IL12/23 blocker ustekinumab. Br J Dermatol 2013; 169: 458–463.

    Article  CAS  Google Scholar 

  28. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273–290.

    Article  CAS  Google Scholar 

  29. Lee YH, Song GG . Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: a meta-analysis. Immunol Invest 2013; 42: 726–736.

    Article  CAS  Google Scholar 

  30. Zhu KJ, Zhu CY, Shi G, Fan YM . Meta-analysis of IL12B polymorphisms (rs3212227, rs6887695) with psoriasis and psoriatic arthritis. Rheumatol Int 2013; 33: 1785–1790.

    Article  CAS  Google Scholar 

  31. Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW et al. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics 2009; 19: 319–323.

    Article  CAS  Google Scholar 

  32. Cañete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1547–1552.

    Article  Google Scholar 

  33. Nishio S, Yamamoto T, Kaneko K, Tanaka-Matsumoto N, Muraoka S, Kaburaki M et al. Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol 2009; 19: 329–333.

    Article  CAS  Google Scholar 

  34. Ramírez J, Fernandez-Sueiro JL, Lopez-Mejias R, Montilla C, Arias M, Moll C et al. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. J Rheumatol 2012; 39: 1035–1041.

    Article  Google Scholar 

  35. Dávila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW et al. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics 2015; 16: 373–381.

    Article  Google Scholar 

  36. Ronpirin C, Tencomnao T, Wongpiyabovorn J . Association between the -1438A/G polymorphism of the serotonin 2A receptor gene and late-onset psoriasis in a Thai population. Genet Mol Res 2010; 9: 208–214.

    Article  CAS  Google Scholar 

  37. Snir O, Hesselberg E, Amoudruz P, Klareskog L, Zarea-Ganji I, Catrina AI et al. Genetic variation in the serotonin receptor gene affects immune responses in rheumatoid arthritis. Genes Immun 2013; 14: 83–89.

    Article  CAS  Google Scholar 

  38. Seddighzadeh M, Korotkova M, Källberg H, Ding B, Daha N, Kurreeman FAS et al. Evidence for interaction between 5-hydroxytryptamine (serotonin) receptor 2A and MHC type II molecules in the development of rheumatoid arthritis. Eur J Hum Genet 2010; 18: 821–826.

    Article  CAS  Google Scholar 

  39. Li Y, Liao W, Chang M, Schrodi SJ, Bui N, Catanese JJ et al. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol 2009; 129: 629–634.

    Article  CAS  Google Scholar 

  40. Elder JT . Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009; 10: 201–209.

    Article  CAS  Google Scholar 

  41. Gao L, Li K, Li F, Li H, Liu L, Wang L et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci 2010; 57: 51–56.

    Article  CAS  Google Scholar 

  42. Shen Z, Chen L, Hao F, Wang G, Liu Y . Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J Cell Mol Med 2010; 14: 226–241.

    Article  CAS  Google Scholar 

  43. O'Neill RT, Temple R . The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 2012; 91: 550–554.

    Article  CAS  Google Scholar 

  44. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437: 369–375.

    Article  CAS  Google Scholar 

  45. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008; 14: 575–581.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Instituto de Salud Carlos III (FIS PI10/01740), Fundación Teófilo Hernando and AbbVie. RP-P has a grant from Universidad Autónoma de Madrid (FPI program 2013). We are grateful to Thomas O’Boyle for editorial assistance and Cristina Carazo for helping to set up the patient databases.

Author information

Author notes

  1. R Prieto-Pérez, G Solano-López and T Cabaleiro: These authors contributed equally to this work.

  2. E Daudén and F Abad-Santos: These two authors contributed equally to this work.

Authors and Affiliations

  1. Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, University Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain

    R Prieto-Pérez, T Cabaleiro, M Román, D Ochoa, M Talegón & F Abad-Santos

  2. Dermatology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain

    G Solano-López & E Daudén

  3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain

    T Cabaleiro & F Abad-Santos

  4. Dermatology Service, Hospital Universitario Gregorio Marañón, Madrid, Spain

    O Baniandrés

  5. Dermatology Service, Hospital Universitario Fundación Alcorcón, Madrid, Spain

    J L López-Estebaranz

  6. Dermatology Service, Hospital Universitario Infanta Leonor, Madrid, Spain

    P de la Cueva

Authors
  1. R Prieto-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Solano-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Cabaleiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Román
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Ochoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Talegón
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O Baniandrés
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L López-Estebaranz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P de la Cueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Daudén
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Abad-Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Abad-Santos.

Ethics declarations

Competing interests

F Abad-Santos has been a consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Farmalíder, Ferrer, GlaxoSmithKline, Gilead, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. E Daudén has potential conflicts of interest (advisory board member, consultant, grants, research support, participation in clinical trials, honoraria for speaking and research support) with the following pharmaceutical companies: AbbVie (Abbott), Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD and Celgene. P de la Cueva has conflicts of interest (advisory board member, consultant, grants, research support, participation in clinical trials, honoraria for speaking and/or research support) with the following pharmaceutical companies: AbbVie (Abbott), Astellas, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD, Gebro, Isdin and Lilly. JL López-Estebaranz has conflicts of interest (advisory board member, speaker or participation in clinical trials) with AbbVie, Amgen, Pfizer, MSD, Janssen-Cilag, Lilly and Celgene. O Baniandrés has conflicts of interest (participation in clinical trials and honoraria for speaking) with the following pharmaceutical companies: AbbVie (Abbott), Janssen-Cilag, Leo Pharma, Pfizer and MSD.

Additional information

Supplementary Information accompanies the paper on The Pharmacogenomics Journal website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prieto-Pérez, R., Solano-López, G., Cabaleiro, T. et al. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics J 18, 70–75 (2018). https://doi.org/10.1038/tpj.2016.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2016.64

This article is cited by

Search

Advanced search

Quick links